← Drug database

Pelzont (laropiprant;nicotinic acid)

Region
🇪🇺 EU
Active substance
laropiprant;nicotinic acid
Company
Merck Sharp Dohme Ltd
Status
Withdrawn
Therapeutic area
Dyslipidemias
EU approval
Thu 03 Jul 2008
Application
EMEA/H/C/000903
ATC
C10AD52
Official record
www.ema.europa.eu

Indication

Pelzont is indicated for the treatment of dyslipidaemia, particularly in patients with combined mixed dyslipidaemia (characterised by elevated levels of low-density-lipoprotein (LDL) cholesterol and triglycerides and low high-density-lipoprotein (HDL)cholesterol) and in patients with primary hypercholesterolaemia (heterozygous familial and non-familial). Pelzont should be used in patients in combination with 3-hydroxy-3-methylglutaryl-coenzyme-A (HMG-CoA)-reductase inhibitors (statins), when the cholesterol lowering effect of HMG-CoA-reductase inhibitor monotherapy is inadequate. It can be used as monotherapy only in patients in whom HMG-CoA-reductase inhibitors are considered inappropriate or not tolerated. Diet and other non-pharmacological treatments (e.g. exercise, weight reduction) should be continued during therapy with Pelzont.

Regulatory milestones

No milestones recorded in the last year.

Same substance in other markets

Follow Pelzont

Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.

Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.